Rationale: Therapies that inhibit CETP (cholesteryl ester transfer protein) have failed to demonstrate a reduction in risk for coronary heart disease (CHD). Human DNA sequence variants that truncate the gene may provide insight into the efficacy of CETP inhibition.
Objective: To test whether protein-truncating variants (PTVs) at the gene were associated with plasma lipid levels and CHD.